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Abstract
Background: Recently an increasing number of digital tools to aid clinical work have been published. This study’s
aim was to create an algorithm which can assist physicians as a “digital expert” with the differential diagnosis of
central ocular motor disorders, in particular in rare diseases.
Results: The algorithm’s input consists of a maximum of 60 neurological and oculomotor signs and symptoms. The
output is a list of the most probable diagnoses out of 14 alternatives and the most likely topographical anatomical
localizations out of eight alternatives. Positive points are given for disease-associated symptoms, negative points for
symptoms unlikely to occur with a disease. The accuracy of the algorithm was evaluated using the two diagnoses
and two brain zones with the highest scores. In a first step, a dataset of 102 patients (56 males, 48.0 ± 22 yrs) with
various central ocular motor disorders and underlying diseases, with a particular focus on rare diseases, was used as
the basis for developing the algorithm iteratively. In a second step, the algorithm was validated with a dataset of
104 patients (59 males, 46.0 ± 23 yrs). For 12/14 diseases, the algorithm showed a sensitivity of between 80 and
100% and the specificity of 9/14 diseases was between 82 and 95% (e.g., 100% sensitivity and 75.5% specificity for
Niemann Pick type C, and 80% specificity and 91.5% sensitivity for Gaucher’s disease). In terms of a topographic
anatomical diagnosis, the sensitivity was between 77 and 100% for 4/8 brain zones, and the specificity of 5/8 zones
ranged between 79 and 99%.
Conclusion: This algorithm using our knowledge of the functional anatomy of the ocular motor system and
possible underlying diseases is a useful tool, in particular for the diagnosis of rare diseases associated with typical
central ocular motor disorders, which are often overlooked.
Keywords: Ocular motor disorder, Algorithm, Niemann pick type C, Gaucher’s disease type 3, Ataxia teleangiectasia,
Ataxia with oculomotor apraxia, Progressive supranuclear palsy, Wernicke encephalopathy
Background
Clinical practice shows that the diagnosis of rare
diseases and central ocular motor disorders is often
difficult, even for neurologists. On the other hand, we
do have detailed knowledge on the anatomy, physi-
ology and pathophysiology of ocular motor disorders,
which allows a precise topographic anatomical diag-
nosis based on bedside examination even without any
laboratory examinations [1] (see Table 3 for a short
description of the most important parts of the clinical
oculomotor examination). This means that, on the
basis of clinical information, we can determine
whether there is an impairment in the midbrain,
pons, medulla or the cerebellar flocculus, nodulus,
vermis, or fastigial nucleus.
Rare diseases, such as Niemann-Pick type C (NPC)
[2], Tay-Sachs (TS) or Gaucher’s disease type 3 (GD 3),
are often overlooked, although the diagnosis can often
be made on the basis of the patient history and clinical
examination and confirmed by genetic testing. Several of
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Ludwig-kraus@gmx.de
1Department of Neurology and German Center for Vertigo and Balance
Disorders, Ludwig-Maximilians University, Munich, Campus Grosshadern,
Marchioninistr. 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
Kraus et al. Orphanet Journal of Rare Diseases          (2019) 14:193 
https://doi.org/10.1186/s13023-019-1164-8
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
48
35
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
these diseases are characterized by quite specific ocular
motor findings, such as a supranuclear saccade or – at a
later stage of the disease – gaze palsy in NPC and TS
(for reference see [1]). From a therapeutic point of view,
these diseases should also not be overlooked because
several of them are treatable nowadays [3, 4].
Facing these problems, we designed a simple and easy-
to-use algorithm to help clinicians to correctly diagnose
central ocular motor disorders and, in particular, associ-
ated rare diseases. Similar approaches have been recently
used to diagnose cerebellar ataxias [5] or vertigo and
dizziness [6].
Methods
The algorithm was created in three steps.
Step one
Two lists were designed: list A contained 14 diseases
which often present with ocular motor disorders, list B
contained 60 signs and symptoms typically found in
these diseases. The latter can be subdivided into two
major groups: general and ocular motor signs and symp-
toms (see Additional file 1).
Subsequently a table with list A in the cross column
and list B in the along column was developed. Based on
the current literature [1, 7, 8], we linked the symptoms
to the diseases by simply entering “Yes” if the symptom
occurs with the disease and “No” if it does not.
By including various diseases, we wanted to give a rep-
resentative clinical overview. Of course, the onset varies
greatly depending on the etiology. In terms of imaging,
even MRI of the brainstem might be normal within the
first 72 h after symptom onset [9], which makes a
systematic clinical examination and topographic diagno-
sis even more relevant. We included the following 14
different diseases: Niemann-Pick disease type C (NPC)
[10, 11], ataxia teleangiectasia (AT) [12–14], ataxia with
oculomotor apraxia 1 and 2 (AOA 1,2) [15], Gaucher’s
disease type 3 (GD 3) [16, 17], Tay-Sachs disease (TS)
[18], Wernicke encephalopathy [19, 20], Huntington’s
chorea [21], multiple sclerosis (MS) [22, 23], Parkinson-
ian syndromes [24], progressive supranuclear palsy (PSP)
[25], tumor, infarction/hemorrhage, inflammatory en-
cephalitis and various cerebellar syndromes (the latter
term sums up diseases which are not a single point on
our list A but cause a cerebellar syndrome like the spi-
nocerebellar ataxias, CANVAS (Cerebellar ataxia with
neuropathy and vestibular areflexia [26]) and Chiari
malformation).
The basic working principle of the algorithm was to
create a score for all of the 14 diseases as an output
following the input of a patient’s signs and symptoms.
The symptoms are entered into an entry mask with
“Yes” if the patient suffers from a symptom, “No” if he
does not and “0” if a symptom was not tested or not
testable (see Additional file 3).
The algorithm was further improved by increasing the
strength of the linking of very typical symptoms to certain
diseases. In the above-mentioned table we entered not
“Yes” but “HR” for “highly related”. If this symptom
occurred, two points instead of one were added to a
disease’s score. We implemented this linking with, e.g.,
“internuclear ophthalmoplegia, aged < 60 years” and “MS”,
“vertical saccade palsy” and “NPC”, “resting tremor” and
“Parkinsonian syndromes”. We also implemented a nega-
tive linking meaning that if a certain symptom occurs, the
score of a disease was decreased. If, for instance, “paresis”
occurs, the score of “NPC” and “GD3” is decreased by two
points to better differentiate it from “TS”.
Step two
The first version of the algorithm was improved using
the data from 102 patients (56 males, 48.0 ± 22 yrs., dis-
tribution of the diseases: NPC - 7, AT - 5, AOA1,2–5,
GD3–7, TS - 5, Wernicke encephalopathy - 5, Hunting-
ton’s chorea - 6, MS - 10, Parkinson syndromes - 9, PSP
- 9, tumor - 4, infarction/hemorrhage - 9, inflammatory
encephalitis - 5, various cerebellar syndromes - 16).
Most of these patients had been examined at our
University Hospital in the past, independently of this
study [3, 17]. We went through the documented oculo-
motor examinations and looked for patients who fulfilled
our criteria. There were two inclusion criteria: 1. they
had to be diagnosed with one and only one of the
diseases in list A, and 2. they had to have oculomotor
disorders which were found and described exactly in the
documentation of the examination. The following exclu-
sion criterion applied: patients had not to have had a
second condition causing oculomotor disorder, such as
brain surgery or a stroke in the past.
We put the clinical findings from these patients into
the entry mask of the algorithm and evaluated its out-
put. Then we adjusted the algorithm in an iterative way
until we reached a good sensitivity and specificity. The
arithmetic procedures we used in the algorithm were
adding zero, one, two, three or four points to the score
or subtracting one, two or three points.
Step three
This was a repetition of step two without further adjust-
ment of the algorithm. We tested if similar results could
be reproduced with a second cohort of 104 patients (59
males, 46.0 ± 23 yrs., distribution of the diseases: NPC -
10, AT - 5, AOA1,2–4, GD3–10, TS - 5, Wernicke
encephalopathy - 5, Huntington’s chorea - 5, MS - 10, Par-
kinson syndromes - 10, PSP - 10, tumor - 4, infarction/
hemorrhage - 11, inflammatory encephalitis - 5, various
cerebellar syndromes - 10).
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We used the same approach as described above to
make the algorithm produce a suggestion on the
topographical anatomical localization of the lesion.
List B with the symptoms remained exactly the
same, while list A with the diseases was changed
into a list of brain zones, which, when affected, re-
sult in ocular motor disorders. Again we used
current literature to link the symptoms to the eight
zones: midbrain, pons, medulla oblongata, basal gan-
glia, frontoparietal cortex and the three parts of the
cerebellum flocculus/paraflocculus, vermis/fastigial
nucleus and nodulus/uvula [8] (see Additional file 2).
We postulated three rules for interpreting the algo-
rithm’s result for the diseases: 1. The result consists of
the two diseases which get the highest scores in the out-
put list (see Additional file 4). This can be more than
two diseases if several get the same score. 2. If the algo-
rithm provides more than five diseases as the result, we
considered this as not helpful. When calculating the dis-
eases’ sensitivity and specificity we counted such results
as false negatives for the actual disease and as false posi-
tives for the other 13 diseases. 3. If one disease’s score
was at least three points higher than any other score,
this disease was considered as the only result of the
algorithm. When the correct diagnosis appeared in the
above-defined result of the algorithm consisting of one
to five diseases we counted the result as a true positive
for the actual disease and a true negative for the other
diseases that did not appear in the result. Every incorrect
one of the one to five result-diseases was counted as a
false positive.
To interpret the algorithm’s result for the topographic
anatomical location we also postulated three rules simi-
lar to but not identical to the rules for the disease: 1.
The result consists of the two brain zones which get the
highest scores in the algorithm’s output list. This can be
more than two zones if several get the same score. 2.
Every score with only one point or less is ignored unless
one point is the highest existing score. 3. If the algo-
rithm provides more than four zones as a result, we con-
sidered this as not helpful and treated it as mentioned
above. The sensitivity and specificity were calculated in
the same way as for the diseases described above.
Approval from the ethics committee board of the
University of Munich was obtained for the study. All in-
vestigations were conducted according to the principles
of the Declaration of Helsinki.
Statistical analysis
For the statistical evaluation, the software “SAS” v9.3
was used. We calculated the confidence limits of the
sensitivity/specificity using an asymptotic normal
approximation to the binomial distribution. The whole
algorithm was then embedded in an easy-to-use web
tool which can be seen in Fig. 1 (called ADOC – Algo-
rithm for the Diagnosis of OCulomotor disorders).
Results
As mentioned in Methods, the algorithm to diagnose
the affected brain structures and diseases was developed
in an iterative way. In the following, the sensitivity and
specificity are given for the last version.
First (“testing”) cohort
In the testing cohort, the sensitivity for the brain zones
lay between 90 and 0% (best: frontoparietal cortex 90%,
basal ganglia 80%, flocculus/paraflocculus 75%). The
specificity was between 98 and 49% (frontoparietal cor-
tex and nodulus/uvula 98%, basal ganglia 96%; and pons
49%).
For the diseases, the sensitivity ranged from 100%
(NPC, AT, AOA1 and 2, GD 3, TS, PSP, Wernicke’s
encephalopathy, inflammatory encephalitis, infarction
/hemorrhage) to 75% (tumor).
As our result design consists of at least two sugges-
tions about the underlying disease in most cases, there
was at least one false positive in every output. So, as
expected, the specificity was not as high, ranging from
96 to 63% (best: infarction/hemorrhage and Parkinson-
ian syndromes 96%, Wernicke’s encephalopathy 95%;
and MS 63%).
Second (“validation”) cohort
The sensitivity and specificity of diseases and brain
zones from the validation cohort can be seen in Tables 1
and 2 respectively. For the brain zones, the sensitivity
ranged from 100 to 0% (medulla oblongata 100%, pons
82%, basal ganglia 79%). The specificity was between 99
and 52% (frontoparietal cortex 99%, nodulus/ uvula 98%,
medulla oblongata 84%; and midbrain 52%).
For the diseases, the sensitivity ranged from 100
(NPC, AOA1 and 2, TS, Wernicke’s encephalopathy,
inflammatory encephalitis, infarction/hemorrhage) to
60% (AT). The specificity was between 95 and 66% (Par-
kinsonian syndromes and Huntington’s chorea 95%, GD
3 92%; and inflammatory encephalitis 66%). In general,
the results of the validation cohort were slightly worse
than in the testing cohort, with the biggest difference be-
ing the sensitivity for AT (5/5 vs. 3/5) (Table 3).
Discussion
The major findings of this study are as follows:
First, this algorithm can be a helpful tool for
diagnosing, in particular, rare diseases associated with
central ocular motor disorders. For example, in the
validation cohort we reached a sensitivity of 100% for
NPC (10/10) and Wernicke’s encephalopathy (5/5). It is
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Fig. 1 Screenshot of the data entry mask in the finished web tool. This excerpt shows the main signs and symptoms categories of the data entry
file. By clicking on “Yes” or “No” one confirms or denies a symptom. Symptoms that were not tested can just be skipped by not clicking on any
of the possibilities and leaving the field empty
Table 1 Sensitivity and specificity for the diseases in the validation cohort. Sensitivity ranged from 100% for NPC, AOA1 and 2, TS,
Wernicke’s encephalopathy, inflammatory encephalitis, infarction/hemorrhage to 60% for AT. Specificity was between 95% for
Parkinsonian syndromes and Huntington’s chorea and 66% for inflammatory encephalitis. Additionally the 95% confidence interval
was calculated for every value
Niemann-Pick disease
Type C (NP-C)
Inflammatory
Encephalitis
Tumor Infarction/
hemorrhage
Multiple
sclerosis
Parkinsonian
syndromes
Progressive
supranuclear palsy
(PSP)
Sensitivity: 10/10 5/5 3/4 11/11 8/10 8/10 8/10
100% 100% 75.0% 100% 80.0% 80.0% 80.0%
95% CI 1.000–1.000 1.000–1.000 0.326–1.000 1.000–1.000 0.552–1.000 0.552–1.000 0.552–1.000
Specificity:
71/94 65/99 82/100 82/93 63/94 89/94 83/94
75.5% 65.7% 82.0% 88.2% 67.0% 94.7% 88.3%
95% CI 0.668–0.842 0.563–0.750 0.745–0.895 0.816–0.947 0.575–0.765 0.901–0.992 0.818–0.948
Wernicke’s
encephalo-pathy
Ataxia
teleangiectasia
Ataxia with
oculomotor apraxia
1/2
Gaucher’s
disease
Type 3 (GD3)
Huntington’s
chorea (HTT)
Cerebellar
syndromes
Tay-Sachs disease
Sensitivity: 5/5 3/5 4/4 8/10 4/5 10/10 5/5
100% 60.0% 100% 80.0% 80.0% 100% 100%
95% CI 1.000–1.000 0.171–1.000 1.000–1.000 0.552–1.000 0.449–1.000 1.000–1.000 1.000–1.000
Specificity:
89/99 86/99 78/100 86/94 94/99 79/94 78/99
89.9% 86.9% 78.0% 91.5% 94.5% 84.0% 78.8%
95% CI 0.840–0.958 0.802–0.935 0.699–0.861 0.858–0.971 0.906–0.993 0.766–0.914 0.707–0.868
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Table 2 Sensitivity and specificity for the brain zones in the validation cohort. Sensitivity ranged from 100% for medulla oblongata
to 0% for nodulus/uvula. Specificity was between 99% for frontoparietal cortex and 52% for midbrain. Additionally the 95%
confidence interval was calculated for every value
Midbrain Pons Medulla
oblongata
Flocculus/
Paraflocculus
Vermis/ Fastigial
Nucleus
Nodulus/
Uvula
Basal
Ganglia
Fronto- parietal
Cortex
Sensitivity: 30/39 28/34 4/4 34/54 14/54 0/54 22/28 5/11
76.9% 82.4% 100% 63.0% 25.9% 0.0% 78.6% 45.5%
95% CI 0.637–
0.901
0.695–
0.952
1.000–1.000 0.501–0.758 0.142–0.376 0.000–0.000 0.634–
0.938
0.160–0.749
Specificity: 30/58 34/63 78/93 25/43 34/43 42/43 57/69 85/86
51.7% 54.0% 83.9% 58.1% 79.1% 97.7% 82.6% 98.8%
95% CI 0.389–
0.646
0.417–
0.663
0.764–0.913 0.434–0.729 0.669–0.912 0.932–1.000 0.737–
0.916
0.966–1.000
Table 3 Different aspects of the clinical oculomotor examination. This table contains a short description of the most important parts
of the clinical oculomotor examination and the possible pathologies which should be looked for
Type of examination Question
Inspection
Head/body posture Tilt or turn of head/body
Position of eyelids Ptosis
Eye position/motility
Position of eyes during straight-ahead gaze Misalignment in primary position,
spontaneous or fixation nystagmus
Horizontal or vertical misalignment
Cover/Uncover test
Examination of eyes in eight positions (binocular and monocular) Determination of range of motility, gaze-evoked nystagmus
(GEN), end-point nystagmus, sustained, unsustained
Gaze-holding function
10–40° in the horizontal GEN:
horizontal, also important for the
diagnosis of downbeat nystagmus
10–20° in the vertical vertical
Back to 0° after 30 s rebound nystagmus
Slow smooth pursuit movements
Horizontal and vertical Smooth or saccadic
Saccades
Horizontal and vertical when looking around or at targets; important
to note: upper eye must be lifted when examining vertical saccades
Latency, velocity, accuracy, conjugacy
Optokinetic nystagmus (OKN)
Horizontal and vertical with OKN drum or tape Inducible, direction, phase (reversal or monocularly diagonal)
Peripheral vestibular function
Head-impulse test (HIT) for the examination of the VOR (Halmagyi–Curthoys
test): rapid turning of the head and fixation of a stationary target; nowadays
better to be done by the video-HIT
Unilateral or bilateral peripheral vestibular deficit
Fixation suppression of the VOR
Turning the head and fixation of a target moving at same speed Impairment of fixation suppression of the VOR
Examination with Frenzel’s or the M-glasses [27]
Straight-ahead gaze, to the right, to the left, downward and upward Peripheral vestibular spontaneous nystagmus
versus central fixation nystagmus
Head-shaking test Head-shaking nystagmus
Kraus et al. Orphanet Journal of Rare Diseases          (2019) 14:193 Page 5 of 7
assumed that both of them are vastly underdiagnosed
[11, 19]. Since these diseases are treatable or, in the
case of Wernicke’s encephalopathy, even curable, an
early diagnosis has a huge impact on the outcome of
these patients.
Second, the results for the brain zones were generally
worse but can still give an indication of where to look
for pathologies in imaging. In the validation cohort, the
sensitivity for involvement of the medulla oblongata
was 100% (4/4) and for the pons 82.4% (28/34).
Third, the algorithm can be applied in less than 5 min.
Compared to “medx” [6], a similar tool recently pub-
lished to diagnose vertigo and dizziness, our algorithm
showed a higher sensitivity (medx: 40 to 80.5%) but a
lower specificity (medx: at least 80%). This can perhaps
be explained by the fact that “medx” focuses on the first
suggested diagnosis, whereas our tool presents the two
top-scoring results. Since our algorithm deals with more
rare diseases, the different approaches seem to be suit-
able for the different problems they are supposed to
solve. Another recent algorithm to diagnose recessive
ataxias is called “RADIAL” [5]. It showed a higher aver-
age sensitivity and specificity (RADIAL: 92.2 and 95.4%,
respectively) than our tool but it works with around
twice as many features (120 vs. 60).
This study has several limitations: First, it was a retro-
spective analysis. Second, our gold standard was the
diagnosis made in the hospital, which is not flawless.
Third, a major problem was that the affected brain zones
could not always be verified in the brain imaging avail-
able or that patients had multiple lesions as in MS.
Regarding the cerebellum, imaging often shows no path-
ologies, however the clinical signs are often specific
based on current knowledge of the function and dys-
function of the flocculus/paraflocculus, nodulus, nucleus
fastigii and dorsal vermis. All in all, however, the major
focus was on the diagnosis of rare diseases which can
evidently be improved by such a simple algorithm.
Conclusions
In summary, this algorithm uses our knowledge on the
functional anatomy of the ocular motor system. It is
based on the simple idea of comparing signs and symp-
toms typical of certain diseases and brain lesions to signs
and symptoms occurring in a certain patient. It is a use-
ful tool for diagnosing diseases, in particular rare ones,
which present with central ocular motor disorders.
Additional files
Additional file 1: Workflow of the algorithm – diseases. These tables
show the working principle of the algorithm using the example of 5 of
the 14 diseases (MS, PSP, Wernicke’s encephalopathy, AT, NPC). Whenever
a symptom occurs in a patient whether the disease’s score is increased
or decreased depends on the type of linking: NEV = − 3, OTTD = − 2,
UL = − 1, N = + 0, Y = + 1, HR = + 2. (DOCX 28 kb)
Additional file 2: Workflow of the algorithm – brain zones. These
tables show the working principle of the algorithm using the example of
4 of the 8 brain zones (midbrain, pons, medulla, flocculus/paraflocculus).
Whenever a symptom occurs in a patient, whether the brain zone’s score
is increased depends on the type of linking: N = + 0, R = + 1, HR = + 2.
(DOCX 20 kb)
Additional file 3: Data entry mask with 3 examples. These tables show
three sample patients’ signs and symptoms entered in the algorithm’s
entry mask. “Yes” means the symptom was present, “No” means it was
not and “0″ it was not looked for in the examination. The real diagnoses
are:1 = PSP, 2 = Wernicke’s Encephalopathy, 3 = NPC. (DOCX 24 kb)
Additional file 4: Output of the algorithm for the input of the 3
examples from Additional file 3. According to our result interpretation
rules (see Methods), the algorithm’s diagnosis suggestions for the three
patients are: Patient 1: brain zone: Basal ganglia and pons; disease: PSP.
Patient 2: brain zone: Pons, medulla oblongata, flocculus/paraflocculus
and vermis/fastigial nucleus; disease: Wernicke’s encephalopathy, MS and
inflammatory encephalitis. Patient 3: brain zone: Midbrain, basal ganglia;
disease: NPC. The real diagnoses are: 1 = PSP, 2 = Wernicke’s
Encephalopathy, 3 = NPC. (DOCX 16 kb)
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